Health Care Equipment

APT released FY2026 Q1 earnings on April 23 During-Market (BJT), actual revenue CNY 704.08 M (forecast CNY 718.77 M), actual EPS CNY 1.63 (forecast CNY 1.567)

APT to Release FY2026 Q1 Earnings on April 24 During-Market (BJT), Forecast Revenue CNY 718.77 M, EPS CNY 1.567

APT to release FY2025 earnings report on March 25 during market hours (BJT), forecast revenue CNY 2.596 B, EPS CNY 5.9115

APT released FY2025 earnings on February 26 During-Market (BJT), actual revenue CNY 2.584 B (forecast CNY 2.596 B), actual EPS CNY 5.8 (forecast CNY 5.9115)

APT released FY2025 Q4 earnings on February 26 During-Market (BJT), actual revenue CNY 716.49 M, actual EPS CNY 1.3902 (forecast EPS CNY 1.3436)

APT released FY2025 9 Months earnings on October 24 After-Market (BJT), actual revenue CNY 1.867 B, actual EPS CNY 4.4135

APT released FY2025 Q3 earnings on October 24 After-Market (BJT), actual revenue CNY 653.63 M, actual EPS CNY 1.4001 (forecast EPS CNY 1.551)

APT to Release FY2025 Q3 Earnings on October 25 After-Market (BJT), Forecast EPS CNY 1.551

APT released FY2025 Q2 earnings on August 21 After-Market BJT, actual revenue CNY 649.53 M, actual EPS CNY 1.7134

APT released FY2025 Semi-Annual Earnings on August 21 After-Market (BJT), Actual Revenue CNY 1.214 B, Actual EPS CNY 3.01

APT to Release FY2025 Semi-Annual Earnings on August 22, 2025 (BJT)

Huati Medical Executive's 减持计划

Huaxi Securities Sees Potential for Huatime Medical's PFA Product in 2025

Multiple Institutions Give Huati Medical a Buy Rating

Huati Medical's Subsidiary Obtains Registration for Coronary Angioplasty Baskets Dilatation Catheter

Significant Merger Integration Success at Mindray and Huati Medical

Ked CNC showcases product and technical advantages, Huite Medical achieves material self-supply

Huabo Fund Conducts Due Diligence on Huite Medical

Huati Medical's 2024 Revenue Growth and New Product Approval

Huati Healthcare Reports High Growth, Electro-physiology Business Upgraded

688617

APT announced that its shareholder Shenzhen Mindray Technology Holdings and its concerted actor Zhuhai Tongsheng Investment increased their holdings in the company by 2.1647 million shares through block trading on the Shanghai Stock Exchange, accounting for 1.54% of the company's total share capital. After the change in equity, Shenzhen Mindray and its concerted actor's total shareholding increased from 35.2534 million shares to 37.4182 million shares, with the shareholding ratio rising from 25.00% to 26.54%. This increase in holdings complies with relevant laws and regulations and will not result in a change in the company's controlling shareholder and actual controller

Zhitong

APT: Shareholder equity changes reach 1% threshold

603626

This week, the largest increase in margin financing and securities lending balance: Kersen margin balance: 603 million yuan, balance increase: 255.59%; APT margin balance: 131 million yuan, balance increase: 152.07%

Kersen

APT announced that its operating revenue in the first half of 2025 was 1.214 billion yuan, a year-on-year increase of 21.26%. Net profit was 425 million yuan, a year-on-year increase of 24.11%

APT: Net profit in the first half of 2025 increased by 24.11% year-on-year

APT's general manager Cheng Zhenghui plans to reduce his holdings by no more than 2.8203 million shares through block trades, accounting for approximately 2% of the company's total share capital. The reduction will take place within three months after the announcement is disclosed, and the total number of shares reduced within any consecutive 90 calendar days will not exceed 2% of the company's total share capital

APT General Manager Cheng Zhenghui plans to reduce his holdings by no more than 2%

Huafu Securities released a research report indicating that domestic electrophysiology device companies are accelerating their layout of PFA (Pulsed Field Ablation) technology, which is expected to usher in its commercialization in 2025. This technology offers higher tissue selectivity and shorter surgical times compared to traditional methods, with the market size expected to grow from 1.3 billion yuan in 2025 to 16.3 billion yuan in 2032, achieving an average annual growth rate of 43.73%. It is recommended to pay attention to domestic manufacturers with three-dimensional mapping systems, as their products have already achieved international competitiveness in terms of cost control and clinical data

Huafu Securities: PFA high prosperity track major products domestic accelerated layout for listing

According to the Zhitong Finance APP, APT announced that its wholly-owned subsidiary Hunan Aipute Medical Devices Co., Ltd. has obtained a medical device registration certificate for a product named: Coronary Artery Stent Balloon Dilatation Catheter. This product is used for pre-dilation treatment of vascular stenosis lesions in adult patients prior to PCI (Percutaneous Coronary Intervention) for stent implantation or balloon use

APT obtained a medical device registration certificate

002653

688521

On May 14, the international index provider MSCI announced the results of its index quarterly adjustments for May 2025, which will take effect after the market closes on May 30, 2024. In this adjustment, the MSCI China Index added 6 stocks, including VeriSilicon, Baillie Gifford, APT, Enlight Media, and Haisco. In addition, the MSCI China Index also removed 17 stocks, including Hisense Home Appliances, FAW Jiefang, Shanghai Pharmaceuticals, and Jincheng Holdings. Since the MSCI China Index is nested within the MSCI Emerging Markets Index, the inclusion of stocks in the MSCI China Index means they also enter the MSCI Global Standard Index series, thereby attracting passive fund tracking

Haisco

VeriSilicon

BIOKIN PHARMACEUTICAL

Enlight Media

SH PHARMA

JCHX

HISENSE HA

FAW Jiefang

MSCI China Index adjustment announced! New additions include VeriSilicon and 6 other constituent stocks

According to the Zhitong Finance APP, APT announced that the company's deputy general manager Han Yonggui has reduced his holdings by 29,900 shares through centralized bidding trading, and this reduction plan has been completed

APT's Deputy General Manager Han Yonggui completed the reduction of 29,900 shares

APT(688617.SH)